Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Neoplasms by Site × pertuzumab × 30 days × Clear all

Sponsor

Conditions

Breast Neoplasms 9 Neoplasms 3 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 HER2-positive Breast Cancer 2 Triple Negative Breast Neoplasms 1 Resectable HER2-positive Breast Cancer 1 Pathologic Complete Response 1 Neoplasm Metastasis 1 Malignant Solid Neoplasm 1 Hemangiosarcoma 1 HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients 1 HER2-positive Early Breast Cancer 1 Endometrial Neoplasms 1 Brain Neoplasms 1 Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

durvalumab 3 Fulvestrant 3 Carboplatin 3 pembrolizumab 2 Pemetrexed 2 Cisplatin 2 trametinib 1 ribociclib 1 pralsetinib 1 palbociclib 1 exemestane 1 darolutamide 1 dabrafenib 1 ceralasertib 1 STX-478 1 Radiosurgery 1 Paclitaxel 1 Letrozole 1 Immunotherapy 1 Gemcitabine 1 Cetuximab 1 Anastrozole 1 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡